Cardiac prevention: The oncologic point of view;Cardioprévention: Le point de vue oncologique

Bulletin du Cancer

Volumn 91, Issue SPEC. ISS., 2004, Pages

  Gligorov, Joseph ^a,b   Debourdeau, Philippe ^b,c   Arsovski, Oliver ^b   Lotz, Jean Pierre ^a,b  

^a HÔPITAL TENON   (France)

^b Assoc Oncol Francomacedonienne   (Macedonia)

^c HIA Desgenettes   (France)

Author keywords

Anthracycline; Cardiac prevention; Cardiac toxicity; Dexrazoxane; Probucol; Taxane; Trastuzumab

Indexed keywords

AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; DOCETAXEL; PACLITAXEL; PROBUCOL; RAZOXANE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG INFUSION; HEART DISEASE; HEART PROTECTION; HUMAN; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

AGE FACTORS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIRUBICIN; HEART; HEART DISEASES; HUMANS; LIPOSOMES; PACLITAXEL; RAZOXANE; RISK FACTORS;

EID: 10044226319     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Petit T. Toxicité cardiaque des anthracyclines. Bull Cancer 2004; 91
2. Campone M, Bourdouloux E, Fumoleau P. Dysfonctionnements cardiaques induits par le trastuzumab. Bull Cancer 2004; 91(special): S166-S179.
3. Saintigny P, Chouahnia K, Charniet JC, Breau JL. Toxicité cardiaque de quelques agents anticancéreux (autres que anthracyclines, fluoropyrimidines et trastuzumab). Bull Cancer 2004; 91(special): S174-S184.
4. Teixeira L, Barry S, Debourdeau P, Cohen A, Tournigand C, et al. Cardiotoxicité du 5-fluoro-uracile. Bull Cancer 2004; 91(special): S154-S158.
5. Giraud P, Cosset JM. La toxicité cardiaque de la radiothérapie: physiopathologie, données cliniques. Bull Cancer 2004; 91(special): S147-S149.
6. Pein F, Iserin L, de Vathaire F, Lemerle J. Toxicité cardiaque des traitements du cancer chez l'enfant et l'adolescent. Physiopathologie, données cliniques et point de vue de l'oncopédiatre. Bull Cancer 2004; 91(special): S185-S191.
7. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
8. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-42.
9. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
10. Lipshultz SE, Lipsjtz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
11. Ferrari E, Gligorov J. Transversales: cardio-oncologie. Oncologie 2003; 5: 147-54.
12. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
13. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62-9.
14. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-63.
15. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237-43.
16. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37: 4-9.
17. Ferrari E, Ferrari P, Talbodec A, Baudouy M. Is Troponin I of prognostic value in the detection of anthracyclin cardiac-toxicity. Eur Heart J 1999; 20: S621.
18. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for monitoring of anthracycline cardiomyopathy: a rebuttal. Pediatrics 1994; 94: 782-4.
19. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004; 91: 37-44.
20. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978; 88: 168-75.
21. Tan C, Tasaka H, Yu KP, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease: clinical evaluation with special reference to childhood leukemia. Cancer 1967; 20: 333-53.
22. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
23. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 1998; 25: 10-4.
24. 2+ binding and lipid peroxydation but depresses myocardial function. Am J Physiol 1986; 250: 419-25.
25. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865-72.
26. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991; 324: 843-5.
27. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989; 25: 873-82.
28. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomized evaluation. Cancer 1990; 65: 870-3.
29. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1998; 63: 37.
30. Valdivieso M, Burgess MA, Ewer MS, et al. Increased therapeutic index of weekly doxorubicin in the therapy of non small cell lung cancer: a prospective randomised study. J Clin Oncol 1984; 2: 207-14.
31. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991; 68: 1221-9.
32. Zalupski M, Metch B, Balcerzak S. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83: 926-32.
33. Ganzina F. 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983; 10: 1-22.
34. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679-88.
35. Launchbuty AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197-228.
36. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18: 3115-24.
37. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-11.
38. Bonneterre J, Roche H, Kerbrat P, et al. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 10-year follow-up results of French Adjuvant Study Group 05 randomized trial. Proc Am Soc Clin Oncol 2003; 22 (abst 93).
39. Bonneterre J, Roche H, kerbrat P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004; 22: 3070-9.
40. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990; 8: 1806-10.
41. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987; 23: 1477-83.
42. Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998; 78: 1634-9.
43. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004; 100: 2052-63.
44. Harris L, Batist G, Belt R, et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast cancer. Cancer 2002; 94: 25-36.
45. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breasrt cancer. J Clin Oncol 2001; 19: 1444-54.
46. Erdkamp F, Chan S, Davidson N, et al. Phase III study of TLC D-99 plus cyclophosphamide versus epirubicin plus cyclophosphamide in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18 abst. 459.
47. Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol 1998; 25: 3-9.
48. Hellmann K. Overview and historical development of dexrazoxane. Semin Oncol 1998; 25: 48-54.
49. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27 [Erratum in. J. Clin. Oncol. 1992; 10: 867].
50. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27 [Erratum in. J. Clin. Oncol. 1992; 10: 867].
51. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-32.
52. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxotubicin-containing therapy. J Clin Oncol 1997; 15: 1333-40.
53. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112-20.
54. Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16: 86-92.
55. Feldman JE, Jones SE, Weisberg SR, et al. Advanced small-cell lung cancer treated with CAV (cyclophosphamide + adriamycin + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard). Proc Am Soc Clin Oncol 1992; 11 (abst. 993).
56. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362-72.
57. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999; 3: 145-59.
58. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracyclin treatement expert panel review. J Cancer Res Clin Oncol 2004; 130: 1-7.
59. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641-8.
60. Herman EH, Zhang J, Rifai N, et al. The use of serum levels of cardiac troponine T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001; 48: 297-304.
61. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-53.
62. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-55.
63. Hellmann K. Dexrazoxane and the Asco guidelines for the use of chemotherapy and radiotherapy protectants: a critique. J Clin Oncol 2000; 18: 2004-6.
64. Schuchter LM, Hensley ML, Meropol NJ, Winer EP, American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-903.
65. Herman EH, Zhang J, Chadwick DP, Ferrans VJ. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 2000; 45: 329-34.
66. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91: 10-5.
67. Iliskovic N, Hasinoff BB, Malisza KL, et al. Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem 1999; 196: 43-9.
68. El-Demerdash E, Ali AA, Sayed-Ahmed MM, Osman AM. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 2003; 52: 411-6.
69. Trastuzumab. Données d'AMM.
70. Cresta S, Grasselli G, Mansutti M, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 2004; 15: 433-9.
71. Ferrari E, Taillan B, Dujardin P, Morand P. Toxicités cardiaques des anthracyclines. Presse Med 1993; 22: 999-1004.
72. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517-22.
73. Noori A, Lindenfeld J, Wolfel E, et al. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 2000; 6: 115-9.
74. Musci M, Loebe M, Grauhan O, et al. Heart transplantation for doxorubicin-induced congestive heart failure in children and adolescents. Transplant Proc 1997; 29: 578-9.
75. Seidman A, Hudis C, Pietri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
76. Alberts DS, Peng YM, Moon TE, Bressler R. Carnitine prevention of adriamycin toxicity in mice. Biomedicine 1978; 29: 265-8.
77. Yaris N, Ceviz N, Coskun T, et al. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J Exp Clin Cancer Res 2002; 21: 165-70.
78. Sayed-Ahmed MM, Shaarawy S, Shouman SA, Osman AM. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol Res 1999; 39: 289-95.